



Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 四川科倫博泰生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(於中華人民共和國註冊成立的股份有限公司)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	: 22,446,100 H Shares (subject to the Over-allotment Option)
Number of Hong Kong Offer Shares	: 2,244,700 H Shares (subject to reallocation)
Number of International Offer Shares	: 20,201,400 H Shares (subject to reallocation and the Over-allotment Option)
Maximum Offer Price	: HK\$72.80 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and the Stock Exchange trading fee of 0.00565% (payable in full on application in Hong Kong Dollars, subject to refund)
Nominal Value	: RMB1.00 per Offer Share
Stock Code	: 6990

全球發售

全球發售的發售股份數目	: 22,446,100股H股(視乎超額配股權行使與否而定)
香港發售股份數目	: 2,244,700股H股(可予重新分配)
國際發售股份數目	: 20,201,400股H股(可予重新分配及視乎超額配股權行使與否而定)
最高發售價	: 每股H股72.80港元, 另加1.0%經紀佣金、0.0027%證監會交易徵費、0.00015%會財局交易徵費及0.00565%聯交所交易費(須於申請時以港元繳足, 多繳股款可予退還)
面值	: 每股發售股份人民幣1.00元
股份代號	: 6990

Please read carefully the prospectus of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") dated June 29, 2023 (the "Prospectus") (in particular, the section on "How to Apply for Hong Kong Offer Shares" in the Prospectus) and the guidelines on the back of this Application Form before completing this Application Form. Terms used in this Application Form shall have the same meanings as those defined in the Prospectus unless defined herein.

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "Stock Exchange"), Hong Kong Securities Clearing Company Limited ("HKSCC"), the Securities and Futures Commission of Hong Kong ("SFC") and the Registrar of Companies in Hong Kong take no responsibility for the contents of this Application Form, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of this Application Form.

A copy of this Application Form, the Prospectus and the other documents specified in the paragraph headed "Documents Delivered to the Registrar of Companies and Available on Display – Documents Delivered to the Registrar of Companies in Hong Kong" in Appendix VIII to the Prospectus, have been registered by the Registrar of Companies in Hong Kong as required by Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). The SFC and the Registrar of Companies of Hong Kong take no responsibility for the contents of these documents.

Your attention is drawn to the paragraph headed "Personal Information Collection Statement" which sets out the policies and practices of the Company and its H Share Registrar in relation to personal data and compliance with the Personal Data (Privacy) Ordinance (Chapter 486 of the Laws of Hong Kong).

Nothing in this Application Form or the Prospectus constitutes or forms a part of any offer to sell or the solicitation of an offer to buy nor shall there be any sale of Hong Kong Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. This Application Form and the Prospectus are not for distribution, directly or indirectly, in or into the United States, nor is this application an offer of Offer Shares for sale in the United States. The Offer Shares have not been and will not be registered under United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities law in the United States and may not be offered, sold, pledged or transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. There will be no public offer of Offer Shares in the United States. The Offer Shares are being offered and sold (1) solely to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

This Application Form and the Prospectus may not be forwarded or distributed or reproduced (in whole or in part) in any manner whatsoever in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction. This Application Form and the Prospectus are addressed to you personally. Any forwarding or distribution or reproduction of this Application Form or the Prospectus in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the U.S. Securities Act or the applicable laws of other jurisdictions.

Allocation of Offer Shares

The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to reallocation as described in the section headed "Structure of the Global Offering" in the Prospectus. In particular, Offer Shares may be reallocated from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Guidance Letter HKEX-GL91-18 issued by the Stock Exchange, if such reallocation is done other than pursuant to clawback mechanism as described in the section headed "Structure of the Global Offering – the Hong Kong Public Offering – Reallocation" in the Prospectus, the maximum total number of Offer Shares available under the Hong Kong Public Offering shall be 4,489,400 Offer Shares, representing approximately 20% of the total number of Offer Shares initially available under the Global Offering and the final Offer Price shall be fixed at the low-end of the indicative Offer Price range (i.e. HK\$60.60 per Offer Share) stated in the Prospectus.

To: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Joint Sponsors
Overall Coordinators
Joint Global Coordinators
Joint Bookrunners
Joint Lead Managers
The Hong Kong Underwriters

在填寫本申請表格前，請細閱四川科倫博泰生物醫藥股份有限公司(「本公司」)日期為2023年6月29日的招股章程(「招股章程」)(尤其是招股章程「如何申請香港發售股份」一節)及本申請表格背面的指引。除非另有界定，否則本申請表格所用詞彙與招股章程所界定者具有相同涵義。

香港交易及結算所有限公司、香港聯合交易所有限公司(「聯交所」)、香港中央結算有限公司(「香港結算」)、香港證券及期貨事務監察委員會(「證監會」)及香港公司註冊處處長對本申請表格的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本申請表格全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。

本申請表格、招股章程及招股章程附錄八「送呈公司註冊處處長及展示文件 – 送呈香港公司註冊處處長文件」一段所述的其他文件已遵照香港法例第32章《公司(清盤及雜項條文)條例》第342C條的規定送呈香港公司註冊處處長登記。香港的證監會及公司註冊處處長對此等文件的內容概不負責。

閣下請留意「個人資料收集聲明」一段，當中載有本公司及其H股證券登記處有關個人資料及遵守香港法例第486章《個人資料(私隱)條例》的政策及慣例。

本申請表格或招股章程所載者概不構成或組成任何出售要約或要約購買的招攬的一部分，而在任何作出有關要約、招攬或出售即屬違法的司法管轄區內，概不得出售任何香港發售股份。本申請表格及招股章程不得在美國境內或向美國直接或間接派發，而此項申請亦非在美國出售發售股份的要約。發售股份並無及不會根據1933年美國《證券法》(經修訂)(「美國《證券法》」)或美國任何州證券法登記，亦不可在美國境內提早發售、出售、質押或轉讓，惟獲豁免遵守美國《證券法》及適用美國州證券法登記規定或不受其規限的交易則除外。將不會於美國進行發售股份的公開發售。發售股份(1)獲豁免根據美國《證券法》登記而僅向合資格機構買家(定義見美國《證券法》第144A條);及(2)根據美國《證券法》S規例於美國境外以離岸交易方式提呈發售及出售。

在任何根據當地法例不得發送、派發或複製本申請表格及招股章程的司法管轄區內概不得以任何方式發送或複製(全部或部分)本申請表格及招股章程。本申請表格及招股章程僅致予閣下本人。概不得發送或派發或複製本申請表格或招股章程的全部或部分。如未能遵守此項指令，可能違反美國《證券法》或其他司法管轄區的適用法律。

發售股份分配

香港公開發售與國際發售之間的發售股份分配將根據招股章程「全球發售的架構」一節所述者予以重新分配。具體而言，發售股份可從國際發售重新分配至香港公開發售以滿足香港公開發售的有效申請。根據聯交所發佈的指引信HKEX-GL91-18，倘並非根據招股章程「全球發售的架構 – 香港公開發售 – 重新分配」一節所述的回補機制進行有關重新分配，則香港公開發售項下可供認購的發售股份總數不得超過4,489,400股發售股份(相當於全球發售項下初步可供認購的發售股份總數約20%)，且最終發售價應釐定為招股章程所載指示性發售價範圍的低位數(即每股發售股份60.60港元)。

致：四川科倫博泰生物醫藥股份有限公司
聯席保薦人
整體協調人
聯席全球協調人
聯席賬簿管理人
聯席牽頭經辦人
香港包銷商

吾等確認，吾等已(i)遵守電子公開發售指引及通過銀行/股票經紀遞交白表eIPO申請的運作程序以及與吾等就香港公開發售提供白表eIPO服務有關的所有適用法律法規(不論法定或其他);及(ii)閣下與本申請表格所載的條款及條件以及申請程序，並同意受其約束。為代表與本申請有關的各項申請人作出申請，吾等：

- 按照招股章程及本申請表格的條款及條件，並在貴公司組織章程大綱及細則的規限下，申請以下數目的香港發售股份；
- 隨附申請香港發售股份所需的全數付款(包括1.0%經紀佣金、0.0027%證監會交易徵費、0.00015%會財局交易徵費及0.00565%聯交所交易費)；
- 確認相關申請人已承諾及同意接納彼等根據本申請所申請的香港發售股份，或彼等根據本申請獲分配的任何較少數目的香港發售股份；
- 承諾及確認相關申請人及相關申請人為其利益提出申請的人士並無申請或接納或表示有意認購或收取或獲配售或分配(包括有條件及/或暫定)國際發售下的任何發售股份，亦不會申請或接納或表示有意認購國際發售下的任何發售股份，亦不會參與國際發售；
- 明白貴公司及整體協調人將依賴該等聲明及陳述而決定是否就本申請配發任何香港發售股份；
- 授權貴公司將相關申請人的姓名/名稱列入貴公司股東名冊內，作為任何將配發予相關申請人的香港發售股份的持有人，並授權貴公司及/或其代理根據本申請表格及招股章程所載程序以普通郵遞方式按相關申請人的申請指示所示地址寄發任何H股股票(如適用)，郵誤風險概由相關申請人自行承擔；
- 要求將任何電子退款指示發送到申請人以單一銀行賬戶繳交申請股款的申請付款銀行賬戶內；
- 要求任何以多個銀行賬戶繳交申請股款之申請人的退款支票以相關申請人(倘屬聯名申請，則為排名首位申請人)為抬頭人，並根據本申請表格及招股章程所述程序以普通郵遞方式按申請指示所示地址寄發任何有關退款支票，郵誤風險概由相關申請人自行承擔；
- 確認各相關申請人已細閱本申請表格、白表eIPO指定網站www.eipo.com.hk及招股章程所載的條款及條件以及申請程序，並同意受其約束；
- 聲明、保證及承諾(a)相關申請人及相關申請人為其利益提出申請的任何人士並不受香港或其他地方之任何適用法律限制就任何香港發售股份提出本申請，支付任何申請股款或獲配發或接納任何香港發售股份及相關申請人及相關申請人為其利益提出申請的任何人士在填寫及提交申請時身處美國境外及屬S規例第902條第(h)(3)段所述的人士且相關申請人及相關申請人為其利益提出申請的任何人士會於離岸交易(定義見S規例)中認購香港發售股份；及(b)向相關申請人或由相關申請人或為其利益而提出本申請的人士配發或申請認購香港發售股份，不會引致貴公司、聯席保薦人、整體協調人、聯席全球協調人、聯席賬簿管理人、聯席牽頭經辦人及香港包銷商或其各自的高級職員或顧問須遵從香港以外任何地區的任何法律或規例(不論是否具有法律效力)的任何規定；及
- 同意本申請、對本申請的任何接納及據此訂立的合約將受香港法例規管並按其詮釋。

We confirm that we have (i) complied with the Guidelines for Electronic Public Offerings and the Operational Procedures for White Form eIPO applications submitted via banks/stock brokers and all applicable laws and regulations (whether statutory or otherwise) in relation to the provision of our White Form eIPO services in connection with the Hong Kong Public Offering; and (ii) read the terms and conditions and application procedures set out in the Prospectus and this application form and agree to be bound by them. Applying on behalf of each of the underlying applicants to whom this application relates, we:

- apply for the number of Hong Kong Offer Shares set out below, on the terms and conditions of the Prospectus and this application form, and subject to the Memorandum and the Articles of Association of the Company;
- enclose payment in full for the Hong Kong Offer Shares applied for, including brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.00565%;
- confirm that the underlying applicants have undertaken and agreed to accept the Hong Kong Offer Shares applied for, or any lesser number allocated to such underlying applicants on this application;
- undertake and confirm that the underlying applicant(s) and the person for whose benefit the underlying applicant(s) is/are applying has/have not applied for or taken up, or indicated an interest for, or received or been placed or allocated (including conditionally and/or provisionally), and will not apply for or take up, or indicate an interest for, any Offer Shares under the International Offering nor otherwise participate in the International Offering;
- understand that these declarations and representations will be relied upon by the Company and the Overall Coordinators in deciding whether or not to make any allotment of Hong Kong Offer Shares in response to this application;
- authorize the Company to place the name(s) of the underlying applicant(s) on the register of members of the Company as the holder(s) of any Hong Kong Offer Shares to be allotted to them, and the Company and/or its agents to send any H Share certificate(s) (where applicable) by ordinary post at that underlying applicant's own risk to the address stated in the application instruction of that underlying applicant in accordance with the procedures prescribed in this application form and in the Prospectus;
- request that any e-Refund payment instructions be despatched to the application payment account where the applicants had paid the application monies from a single bank account;
- request that any refund cheque(s) be made payable to the underlying applicant (in the case of joint applications, the first-named applicant) who had used multiple bank accounts to pay the application monies and to send any such refund cheque(s) by ordinary post at that underlying applicant's own risk to the address stated on the application in accordance with the procedures prescribed in this application form and in the Prospectus;
- confirm that each underlying applicant has read the terms and conditions and application procedures set out in this application form, on the designated White Form eIPO website at www.eipo.com.hk and in the Prospectus, and agrees to be bound by them;
- represent, warrant and undertake (a) that the underlying applicant(s) and any persons for whose benefit the underlying applicant(s) is/are applying is not restricted by any applicable laws of Hong Kong or elsewhere from making this application, paying any application monies for, or being allocated or taking up, any Hong Kong Offer Shares and the underlying applicant(s) and any persons for whose benefit the underlying applicant(s) is/are applying is/are outside the United States when completing and submitting the application and is/are a person described in paragraph (h)(3) of Rule 902 of Regulation S and the underlying applicant(s) and any persons for whose benefit the underlying applicant(s) is/are applying will acquire the Hong Kong Offer Shares in an offshore transaction (within the meaning of Regulation S); and (b) that the allocation of or application for the Hong Kong Offer Shares to the underlying applicant or by underlying applicant or for whose benefit this application is made would not require the Company, the Joint Sponsors, the Overall Coordinators, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers and the Hong Kong Underwriters or their respective officers or advisers to comply with any requirements under any law or regulation (whether or not having the force of law) of any territory outside Hong Kong; and
- agree that this application, any acceptance of it and the resulting contract, will be governed by and construed in accordance with the laws of Hong Kong.

Signature 簽名	
Name of signatory 簽署人姓名	

Date 日期	
Capacity 身份	

2 We, on behalf of the underlying applicants, offer to purchase 吾等(代表相關申請人)提出認購

Total number of H Shares H股總數	
----------------------------------	--

Hong Kong Offer Shares on behalf of the underlying applicants whose details are contained in the read-only CDROM submitted with this Application Form.
代表相關申請人(其詳細資料載於連同本申請表格遞交的唯讀光碟)提出認購的香港發售股份。

3 A total of 隨附合共

cheque(s) 支票數目	Cheque number(s) 支票編號
are enclosed for a total sum of 其總金額為	Name of bank 銀行名稱
HK\$	港元

4 Please use BLOCK letters 請用正楷填寫

Name of White Form eIPO Service Provider in English 白表eIPO服務供應商英文名稱	White Form eIPO Service Provider ID 白表eIPO服務供應商編號	
Chinese name 中文名稱	Contact number 聯絡電話號碼	Fax number 傳真號碼
Name of contact person 聯絡人姓名	For Broker use 此欄供經紀填寫 Lodged by 申請由以下經紀遞交	
Address 地址	Broker no. 經紀號碼	
	經紀印章	

For Broker use 此欄供銀行填寫

GUIDELINES TO COMPLETING THIS APPLICATION FORM

References to boxes below are to the numbered boxes on this Application Form.

1 Sign and date the Application Form in Box 1. Only a written signature will be accepted.

The name and the representative capacity of the signatory should also be stated.

To apply for Hong Kong Offer Shares using this Application Form, you must be named in the list of White Form eIPO Service Providers who may provide White Form eIPO services in relation to the Hong Kong Public Offering, which was released by the SFC.

2 Put in Box 2 (in figures) the total number of Hong Kong Offer Shares for which you wish to apply on behalf of the underlying applicants.

Application details of the underlying applicants on whose behalf you are applying must be contained in one data file in read-only CD-ROM format submitted together with this Application Form.

3 Complete your payment details in Box 3.

You must state in this box the number of cheque(s) you are enclosing together with this Application Form; and you must state on the reverse of each of those cheque(s) (i) your White Form eIPO Service Provider ID; and (ii) the file number of the data file containing application details of the underlying applicant(s).

The dollar amount(s) stated in this box must be equal to the amount payable for the total number of Hong Kong Offer Shares applied for in Box 2. All cheque(s) and this Application Form together with a sealed envelope containing the CD-ROM, if any, must be placed in the envelope bearing your company chop.

For payments by cheque, the cheque must:

- be in Hong Kong dollars;
- not be post dated;
- be drawn on a Hong Kong dollar bank account with a licensed bank in Hong Kong;
- show your (or your nominee's) account name;
- be made payable to "ICBC (ASIA) NOMINEE LIMITED – SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL PUBLIC OFFER";
- be crossed "Account Payee Only"; and
- be signed by the authorized signatories of the White Form eIPO Service Provider.

Your application may be rejected if any of these requirements is not met or if the cheque is dishonored on its first presentation.

It is your responsibility to ensure that details on the cheque(s) submitted correspond with the application details contained in the CD-ROM or data file submitted in respect of this application. The Company and the Overall Coordinators have full discretion to reject any applications in the case of discrepancies.

No receipt will be issued for sums paid on application.

4 Insert your details in Box 4 (using BLOCK letters).

You should write the name, ID and address of the White Form eIPO Service Provider in this box. You should also include the name and telephone number of the contact person at your place of business and where applicable, the Broker No. and Broker's Chop.

Personal Information Collection Statement

The main provisions of the Personal Data (Privacy) Ordinance (Chapter 486 of the Laws of Hong Kong) (the "Ordinance") came into effect on December 20, 1996. This Personal Information Collection Statement informs the applicant for and holder of the H Shares of the policies and practices of the Company and the H Share Registrar in relation to personal data and the Ordinance.

1. Reasons for the collection of your personal data

From time to time it is necessary for applicants for securities or registered holders of securities to supply their latest correct personal data to the Company and/or the H Share Registrar when applying for securities or transferring securities into or out of their names or in procuring the services of the H Share Registrar.

Failure to supply the requested data may result in your application for securities being rejected or in delay or the inability of the Company and/or the H Share Registrar to effect transfers or otherwise render their services. It may also prevent or delay registration or transfer of the Hong Kong Offer Shares which you have successfully applied for and/or the dispatch of H Share certificate(s), and/or the dispatch of e-Refund payment instructions, and/or the dispatch of refund cheque(s) to which you are entitled.

It is important that the applicants and the holders of securities inform the Company and the H Share Registrar immediately of any inaccuracies in the personal data supplied.

2. Purposes

The personal data of the applicants and holders of securities may be used, held and/or stored (by whatever means) for the following purposes:

- processing of your application and e-Refund payment instructions/refund cheque, where applicable, and verification of compliance with the terms and application procedures set out in this Application Form and the Prospectus and announcing results of allocation of the Hong Kong Offer Shares;
- enabling compliance with all applicable laws and regulations in Hong Kong and elsewhere;
- registering new issues or transfers into or out of the names of holders of securities including, where applicable, in the name of HKSCC Nominees;
- maintaining or updating the registers of holders of securities of the Company;
- conducting or assisting to conduct signature verifications, any other verification or exchange of information;
- establishing benefit entitlements of holders of securities of the Company, such as dividends, rights issues and bonus issues, etc.;
- distributing communications from the Company and its subsidiaries;
- compiling statistical information and Shareholder profiles;
- making disclosures as required by laws, rules or regulations;
- disclosing identities of successful applicants by way of press announcement(s) or otherwise;
- disclosing relevant information to facilitate claims on entitlements; and
- any other incidental or associated purposes relating to the above and/or to enable the Company and the H Share Registrar to discharge their obligations to holders of securities and/or regulators and any other purpose to which the holders of securities may from time to time agree.

3. Transfer of personal data

Personal data held by the Company and the H Share Registrar relating to the applicants and the holders of securities will be kept confidential but the Company and its H Share Registrar may, to the extent necessary for achieving the above purposes or any of them, make such enquiries as they consider necessary to confirm the accuracy of the personal data and in particular, they may disclose, obtain or transfer (whether within or outside Hong Kong) the personal data of the applicants and the holders of securities to, from or with any and all of the following persons and entities:

- the Company or its appointed agents such as financial advisers, receiving banks and overseas principal registrars;
- where applicants for securities request deposit into CCASS, HKSCC and HKSCC Nominees, who will use the personal data for the purposes of operating CCASS;
- any agents, contractors or third-party service providers who offer administrative, telecommunications, computer, payment or other services to the Company and/or the H Share Registrar in connection with the operation of their respective businesses;
- the Stock Exchange, the SFC and any other statutory, regulatory or governmental bodies, or otherwise as required by laws, rules or regulations; and
- any other persons or institutions with which the holders of securities have or propose to have dealings, such as their bankers, solicitors, accountants, or stockbrokers, etc.

4. Retention of Personal Data

The Company and the H Share Registrar will keep the personal data of the applicants and holders of securities for as long as necessary to fulfil the purposes for which the personal data were collected. Personal data which is no longer required will be destroyed or dealt with in accordance with the Ordinance.

5. Access and correction of personal data

The Ordinance provides the applicants and the holders of securities with rights to ascertain whether the Company and/or the H Share Registrar hold their personal data, to obtain a copy of that data, and to correct any data that is inaccurate. In accordance with the Ordinance, the Company and the H Share Registrar have the right to charge a reasonable fee for the processing of any data access request. All requests for access to data or correction of data or for information regarding policies and practices and the kinds of data held should be addressed to the Company for the attention of the Company Secretaries or (as the case may be) the H Share Registrar for the attention of the privacy compliance officer for the purposes of the Ordinance.

By signing this Application Form, you agree to all of the above.

DELIVERY OF THIS APPLICATION FORM

This completed Application Form, together with the appropriate cheque(s) together with a sealed envelope containing the CD-ROM, must be submitted to the following receiving bank by Tuesday, July 4, 2023 at 4:00 p.m.:

Industrial and Commercial Bank of China (Asia) Limited
Level 16, Tower 1
Millennium City 1
388 Kwun Tong Road
Kowloon, Hong Kong

填寫本申請表格的指引

下文各欄提述的號碼乃本申請表格中各欄的編號。

1 在申請表格欄1簽署及填上日期。只接受親筆簽名。

亦必須註明簽署人的姓名／名稱及代表身份。

如欲使用本申請表格申請認購香港發售股份，閣下必須為名列於證監會公佈的白表eIPO服務供應商名單內可就香港公開發售提供白表eIPO服務的供應商。

2 在欄2填上 閣下欲代表相關申請人申請認購的香港發售股份總數（以數字填寫）。

閣下代表相關申請人作出申請的詳細申請資料必須包含於連同本申請表格一併遞交的唯讀光碟格式的一個資料檔案內。

3 在欄3填上 閣下付款的詳細資料。

閣下必須在本欄註明 閣下連同本申請表格隨附的支票數目；及 閣下必須在每張支票的背面註明(i) 閣下的白表eIPO服務供應商編號；及(ii)載有相關申請人詳細申請資料的資料檔案編號。

本欄所註明的金額必須與欄2所申請認購的香港發售股份總數應付金額相同。所有支票及本申請表格連同裝有唯讀光碟的密封信封（如有）必須放進蓋有 閣下公司印章的信封內。

如以支票繳付股款，則該支票必須：

- 以港元開出；
- 不得為期票；
- 由在香港持牌銀行開設的港元銀行賬戶開出；
- 顯示 閣下（或 閣下代名人）的賬戶名稱；
- 註明抬頭人為「工銀亞洲代理人有限公司－四川科倫博泰生物醫藥公開發售」；
- 劃線註明「只准入抬頭人賬戶」；及
- 由白表eIPO服務供應商的授權簽署人簽署。

倘未能符合任何此等規定或倘支票首次過戶不獲兌現，閣下的申請可能會遭拒絕受理。

閣下有責任確保所遞交支票上的詳細資料與就本申請遞交的唯一讀光碟或資料檔案所載的申請詳情相同。倘出現差異，本公司及整體協調人有絕對酌情權拒絕接受任何申請。

申請時繳付的款項將不會獲發收據。

4 在欄4填上 閣下的詳細資料（用正楷填寫）。

閣下必須在本欄填上白表eIPO服務供應商的名稱、編號及地址。閣下亦應填寫 閣下營業地點的聯絡人姓名及電話號碼及（如適用）經紀號碼及加蓋經紀印章。

個人資料收集聲明

香港法例第486章《個人資料（私隱）條例》（「《條例》」）中的主要條文於1996年12月20日生效。此份個人資料收集聲明是向H股申請人及持有人說明本公司及H股證券登記處有關個人資料及《條例》的政策及慣例。

1. 收集 閣下個人資料的原因

證券申請人或證券登記持有人以其名義申請證券或轉讓或受讓證券時或尋求H股證券登記處的服務時，須不時向本公司及／或H股證券登記處提供其最新的正確個人資料。

未能提供所需資料可能會導致 閣下的證券申請遭拒絕受理或延遲或本公司及／或H股證券登記處無法進行證券轉讓或提供服務。此舉亦可能妨礙或延誤 閣下成功申請的香港發售股份登記或過戶及／或妨礙或延誤寄發H股股票，及／或發送電子退款指示，及／或寄發 閣下應得的退款支票。

證券申請人及持有人提供的個人資料如有任何錯誤，須立即通知本公司及H股證券登記處。

2. 目的

證券申請人及持有人的個人資料可以任何方式被採用、持有及／或保存，以作下列用途：

- 處理 閣下的申請及電子退款指示／退款支票（如適用）、核實是否遵守本申請表格及招股章程所載條款及申請程序以及公佈香港發售股份的分配結果；
- 以遵守香港及其他地區的一切適用法律法規；
- 以證券持有人（包括香港結算代理人（如適用）的名義登記新發行證券或轉讓或受讓證券；
- 存置或更新本公司證券持有人名冊；
- 進行或協助進行簽名核對或任何其他資料的核對或交換；
- 確定本公司證券持有人的受益權利，例如股息、供股和紅股等；
- 分發本公司及其附屬公司的通訊資料；
- 編製統計資料及股東資料；
- 遵照法例、規則或規例的要求作出披露；
- 通過報章公佈或其他方式披露獲接納申請人的身份；
- 披露有關資料以便就權益索償；及
- 與上述有關的任何其他附帶或相關用途及／或使本公司及H股證券登記處能夠履行對證券持有人及／或監管機構承擔的責任及證券持有人不時同意的任何其他用途。

3. 轉交個人資料

本公司及其H股證券登記處將對所持有關證券申請人及持有人的個人資料進行保密，但本公司及其H股證券登記處可能會在為達到上述用途或上述任何用途之必要情況下作出彼等認為必要的查詢以確認個人資料的準確性，尤其可能會向下列任何及所有人士及實體披露、獲取或轉交（不論在香港境內或境外）證券申請人及持有人的個人資料：

- 本公司或其委任的代理，例如財務顧問、收款銀行及海外證券登記總處；
- （如證券申請人要求將證券存入中央結算系統）香港結算及香港結算代理人，彼等將就運作中央結算系統使用有關個人資料；
- 向本公司及／或H股證券登記處提供與其各自業務營運有關的行政、電訊、電腦、付款或其他服務的任何代理、承包商或第三方服務供應商；
- 聯交所、證監會及任何其他法定、監管或政府機關或法例、規則或規例另行規定者；及
- 證券持有人與其進行或擬進行交易的任何其他人士或機構，例如彼等的銀行、律師、會計師、或股票經紀等。

4. 保留個人資料

本公司及H股證券登記處將按收集個人資料所需的用途保留證券申請人及持有人的個人資料。無需保留的個人資料將會根據《條例》銷毀或處理。

5. 查閱和更正個人資料

《條例》賦予證券申請人及持有人權利以確定本公司及／或H股證券登記處是否持有其個人資料、索取有關資料的副本及更正任何不準確資料。根據《條例》，本公司和H股證券登記處有權就處理任何查閱資料的要求收取合理費用。根據《條例》，所有關於查閱資料、更正資料或索取關於政策及慣例的資料及所持資料類別的要求，應向本公司的公司秘書或H股證券登記處屬下的私隱事務主任（視情況而定）提出。

閣下簽署本申請表格，即表示同意上述各項。

遞交本申請表格

經填妥的本申請表格，連同相關支票及裝有相關唯讀光碟的密封信封，必須於2023年7月4日（星期二）下午四時正之前，送達下列收款銀行：

中國工商銀行（亞洲）有限公司
香港九龍
觀塘道388號
創紀之城1期1座16樓